Inhalon Biopharma

Developing inhaled antibody treatments for acute respiratory infections, a clinical-stage biotechnology company

placeMorrisville, North Carolina, United States calendar_todayFounded 2018 groups8 employees language inhalon.com

Innovation

3 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 7 times.

YearFilings
20232
20241
20252

Social engagement

Social engagement: 830 social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

7 investors on record; lead investors include QB3.

Investor typeCountShare
Venture capital343%
Private equity114%
Accelerator & incubator114%
Other / undisclosed229%
Coming soon